Toward an Era of Biopsy‑Free Clinical Trials? Noninvasive Diagnostic Technologies Are Transforming Liver Disease Research
Recent FDA deliberations on employing noninvasive diagnostics as surrogate endpoints in MASH drug‑development trials have drawn wide attention. MASH—formerly referred to as non‑alcoholic steatohepatitis (NASH)—is characterized by excessive hepatic fat accumulation with inflammation and fibrosis (scarring). Progression can lead to…